ClinicalTrials.gg
CompletedNCT03496324Updated Jun 5, 2019Results posted

Ibuprofen 4% (w/v) Pivotal Bioequivalence Study

A Phase 1 interventional study of Nurofen for Children® and Algifor® Junior in Bioequivalence of the Test Formulation, sponsored by Reckitt Benckiser Healthcare (UK) Limited. Completed. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-05.

Sponsored by Reckitt Benckiser Healthcare (UK) Limited (part of Reckitt) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Feb 2016, registered Apr 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Bioequivalence evaluation of Nurofen for Children® with reference formulation of Algifor® Junior by determining and comparing the rate and extent of absorption in both fed and fasted states

02

Conditions studied

  • Bioequivalence of the Test Formulation
03

In context

Lead sponsor

Reckitt Benckiser Healthcare (UK) Limited is the lead sponsor of 35 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who had given written .
  2. Age: ≥18 years ≤50 years.
  3. Sex: Male or female subjects who were eligible for entry.
  4. Female subject of with a negative pregnancy test at the screening visit and who were willing to use an effective method of , if applicable (unless of non-childbearing potential or where abstaining from sexual intercourse was in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after the final dose of Medicinal Product (IMP). Effective forms of contraception included: established use of oral, injected or implanted hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, male sterilisation (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate).
  5. Female subject of non-child bearing potential with negative pregnancy test at the screening visit. For the purposes of this study, this was defined as the subject being amenorrheic for at least 12 consecutive months or at least 4 months post-surgical sterilisation (including bilateral fallopian tube ligation or bilateral oophorectomy with or without hysterectomy). Menopausal status was confirmed by demonstrating at screening that levels of follicle stimulating hormone (FSH) fell within the respective pathology reference range. In the event a subject's menopause status had been clearly established (for example, the subject indicated she had been amenorrheic for 10 years), but FSH levels were not consistent with a condition, determination of subject eligibility was at the discretion of the Principal Investigator following consultation with the Sponsor's Responsible Physician.
  6. Male subject willing to use an effective method of contraception, if applicable (unless anatomically sterile or where abstaining from sexual intercourse in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after the final dose of IMP.
  7. Healthy subjects as determined by past medical history, physical examination, vital signs, (ECG), and laboratory tests at screening.
  8. Healthy subjects with a (BMI) of ≥20 and ≤27 kg/m2.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating females.
  2. A history and/or presence of significant disease of any body system, including psychiatric disorders as specified in Chapter 5 of the International Classification of Diseases (ICD) 10.
  3. Any condition that may have interfered with the absorption, distribution, metabolism or excretion of drugs.
  4. A history of allergy or intolerance (including angioedema, urticaria, bronchospasm and rhinitis) related to treatment with ibuprofen, aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs), or the of the formulations.
  5. A history of or active peptic or duodenal ulcers or gastrointestinal bleed or upper gastro-intestinal bleed, or other significant gastro-intestinal disorders.
  6. A history of frequent dyspepsia, e.g. heartburn or indigestion.
  7. A history of migraine.
  8. Users of nicotine products i.e. current smokers and ex-smokers who had smoked within the 6 months prior to dosing with the study medication or users of cigarette replacements (e.g. e-cigarettes, nicotine patches or gums).
  9. A history of substance abuse (including alcohol).
  10. High consumption of stimulating drinks (coffee, tea, cola, energy drinks etc. total caffeine intake per day above 300 mg (1 cup of coffee equated to 50 mg)).
  11. Those with positive screen/test for drugs of abuse including alcohol on any occasion throughout the study.
  12. Ingestion of a prescribed drug at any time in the 14 days before dosing with study medication (excluding hormonal and hormone replacement therapy), or consumption of enzyme inhibitors or inducers during the previous month (such as barbiturates, carbamazepine, erythromycin, phenytoin, etc.).
  13. Ingestion of an over-the-counter preparation within 7 days before dosing with study medication, including herbal medications, vitamin/fish oil supplements, ibuprofen and other NSAID.
  14. Donation of blood in quantity >400 mL, e.g., to the blood transfusion service in the previous 12 weeks before enrolment into the study.
  15. Known human immune deficiency virus () positive status, or a positive viral serology screen.
  16. Topical use of ibuprofen within 7 days before dosing with IMP.
  17. Those previously randomized into this study.
  18. Employee at study site.
  19. Partner or first degree relative of the Investigator.
  20. Those who have participated in a clinical trial in the previous 12 weeks.
  21. Those unable, in the opinion of the Investigator, to comply fully with the study requirements.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Test (fed): Nurofen for Children

    Nurofen for Children® 400 mg/10 ml by mouth under fed condition Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.

    Drug: Nurofen for Children®

  • Active comparator
    Test (fasted): Nurofen for Children

    Nurofen for Children® 400 mg/10 ml by mouth under fasted condition. Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.

    Drug: Nurofen for Children®

  • Experimental
    Reference (fed): Algifor Junior

    Algifor® Junior 400 mg/20 ml by mouth under fed condition. Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.

    Drug: Algifor® Junior

  • Experimental
    Reference (fasted): Algifor Junior

    Algifor® Junior 400 mg/20 ml by mouth under fasted condition. Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA.

    Drug: Algifor® Junior

Interventions

  • DrugNurofen for Children®

    Nurofen for Children® 400 mg/10 ml

    Also known as: NfC®

  • Algifor® Junior 400 mg/20 ml

    Also known as: Ibuprofen oral suspension

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of Ibuprofen

    One Subject in Period 3 Reference (fasted) was not included in PK Parameter Summary Set as per statistical analysis plan (SAP) Population definitions.

    Time frame: Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose

  2. Area Under Plasma Concentration-time Curve From Administration to the Last Quantifiable Concentration at Time t (AUC0-t) of Ibuprofen

    Time frame: Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose

Secondary outcomes

  1. Elimination Rate Constant (Kel) of Ibuprofen

    Kel was calculated as the absolute value of the log-linear regression slope of the elimination phase (logged) over time (linear) using the post Cmax concentrations \[at least 3 non-below the limit of quantification (BLQ)\] that maximized the adjusted R2.

    Time frame: Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose

  2. Area Under Plasma Concentration-time Curve From Administration to Infinity (AUC0-inf) of Ibuprofen

    AUC0-inf was calculated as AUC0-t + (Ct/Kel) where Ct was the last quantifiable concentration at time t.

    Time frame: Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose

  3. Ratio of AUC0-t/AUC0-inf (AUCR)

    Time frame: Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose

  4. Time to Maximum Plasma Concentration (Tmax) of Ibuprofen

    Time frame: Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose

  5. Plasma Concentration Half-life (T1/2) of Ibuprofen

    Time frame: Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose

  6. Number of Subjects With Treatment Emergent Adverse Events (TEAEs)

    Mild = Adverse event (AE) did not limit usual activities; subject may have experienced slight discomfort. Moderate = AE resulted in some limitation of usual activities; subject may have experienced significant discomfort. Severe = AE resulted in an inability to carry out usual activities; subject may have experienced intolerable discomfort/pain. Unassessable/Unclassified = Insufficient information to be able to make an assessment Conditional/ Unclassified = Insufficient information to make an assessment at present Unrelated = No possibility that the AE was caused by the IMP Unlikely = Slight, but remote, chance that the AE was caused by the IMP, but the balance of judgment was that it was most likely not due to the investigational medicinal product (IMP). Possible = Reasonable suspicion that the AE was caused by the IMP Probable = Most likely that the AE was caused by the IMP Certain = AE was definitely caused by the IMP

    Time frame: Up to Day 7 (follow-up)

07

Results

Posted Jun 5, 2019

Participant flow

Study was conducted in single-site in the United Kingdom.

Period 1
Participant flow — Period 1
MilestoneSequence 1-BACD: Test (Fed) - Nurofen for ChildrenSequence 2-DCAB: Test (Fasted) - Nurofen for ChildrenSequence 3-ADBC: Reference (Fed) - Algifor JuniorSequence 4-CBDA: Reference (Fasted) - Algifor Junior
Started6666
Completed6666
Not completed0000
Period 1: Washout (3 to 7 Days)
Participant flow — Period 1: Washout (3 to 7 Days)
MilestoneSequence 1-BACD: Test (Fed) - Nurofen for ChildrenSequence 2-DCAB: Test (Fasted) - Nurofen for ChildrenSequence 3-ADBC: Reference (Fed) - Algifor JuniorSequence 4-CBDA: Reference (Fasted) - Algifor Junior
Started6666
Completed6666
Not completed0000
Period 2
Participant flow — Period 2
MilestoneSequence 1-BACD: Test (Fed) - Nurofen for ChildrenSequence 2-DCAB: Test (Fasted) - Nurofen for ChildrenSequence 3-ADBC: Reference (Fed) - Algifor JuniorSequence 4-CBDA: Reference (Fasted) - Algifor Junior
Started6666
Completed6666
Not completed0000
Period 2: Washout (3 to 7 Days)
Participant flow — Period 2: Washout (3 to 7 Days)
MilestoneSequence 1-BACD: Test (Fed) - Nurofen for ChildrenSequence 2-DCAB: Test (Fasted) - Nurofen for ChildrenSequence 3-ADBC: Reference (Fed) - Algifor JuniorSequence 4-CBDA: Reference (Fasted) - Algifor Junior
Started6666
Completed6666
Not completed0000
Period 3
Participant flow — Period 3
MilestoneSequence 1-BACD: Test (Fed) - Nurofen for ChildrenSequence 2-DCAB: Test (Fasted) - Nurofen for ChildrenSequence 3-ADBC: Reference (Fed) - Algifor JuniorSequence 4-CBDA: Reference (Fasted) - Algifor Junior
Started6666
Completed6666
Not completed0000
Period 3: Washout (3 to 7 Days)
Participant flow — Period 3: Washout (3 to 7 Days)
MilestoneSequence 1-BACD: Test (Fed) - Nurofen for ChildrenSequence 2-DCAB: Test (Fasted) - Nurofen for ChildrenSequence 3-ADBC: Reference (Fed) - Algifor JuniorSequence 4-CBDA: Reference (Fasted) - Algifor Junior
Started6666
Completed6666
Not completed0000
Period 7: Period 4
Participant flow — Period 7: Period 4
MilestoneSequence 1-BACD: Test (Fed) - Nurofen for ChildrenSequence 2-DCAB: Test (Fasted) - Nurofen for ChildrenSequence 3-ADBC: Reference (Fed) - Algifor JuniorSequence 4-CBDA: Reference (Fasted) - Algifor Junior
Started6666
Completed6666
Not completed0000

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax) of Ibuprofen

One Subject in Period 3 Reference (fasted) was not included in PK Parameter Summary Set as per statistical analysis plan (SAP) Population definitions.

Time frame:
Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose
Reported as:
Mean · μg/ml
Maximum Plasma Concentration (Cmax) of Ibuprofen
μg/mlTest (Fasted): Nurofen for ChildrenTest (Fed): Nurofen for ChildrenReference (Fasted): Algifor JuniorReference (Fed): Algifor Junior
Maximum Plasma Concentration (Cmax) of Ibuprofen38.503 ± 7.569625.162 ± 6.966833.843 ± 3.785826.432 ± 6.129
Statistical analysis
  • Test (Fed): Nurofen for Children vs Reference (Fed): Algifor Junior · Geometric least square mean: 94.19 · 90% CI 85.81 to 103.38
  • Test (Fasted): Nurofen for Children vs Reference (Fasted): Algifor Junior · Geometric least square mean: 111.66 · 90% CI 103.84 to 120.07
PrimaryArea Under Plasma Concentration-time Curve From Administration to the Last Quantifiable Concentration at Time t (AUC0-t) of Ibuprofen
Time frame:
Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose
Reported as:
Mean · min*μg/mL
Area Under Plasma Concentration-time Curve From Administration to the Last Quantifiable Concentration at Time t (AUC0-t) of Ibuprofen
min*μg/mLTest (Fasted): Nurofen for ChildrenTest (Fed): Nurofen for ChildrenReference (Fasted): Algifor JuniorReference (Fed): Algifor Junior
Area Under Plasma Concentration-time Curve From Administration to the Last Quantifiable Concentration at Time t (AUC0-t) of Ibuprofen6169.662 ± 1199.17855754.831 ± 1056.50145960.054 ± 832.13425482.340 ± 827.2913
Statistical analysis
  • Test (Fasted): Nurofen for Children vs Reference (Fasted): Algifor Junior · Geometric least square mean: 101.57 · 90% CI 96.28 to 107.16
  • Test (Fed): Nurofen for Children vs Reference (Fed): Algifor Junior · Geometric least square mean: 104.47 · 90% CI 101.4 to 107.63
SecondaryElimination Rate Constant (Kel) of Ibuprofen

Kel was calculated as the absolute value of the log-linear regression slope of the elimination phase (logged) over time (linear) using the post Cmax concentrations \[at least 3 non-below the limit of quantification (BLQ)\] that maximized the adjusted R2.

Time frame:
Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose
Reported as:
Mean · 1/min
Elimination Rate Constant (Kel) of Ibuprofen
1/minTest (Fasted): Nurofen for ChildrenTest (Fed): Nurofen for ChildrenReference (Fasted): Algifor JuniorReference (Fed): Algifor Junior
Elimination Rate Constant (Kel) of Ibuprofen0.00646 ± 0.0007630.00532 ± 0.001190.00668 ± 0.0007630.00577 ± 0.000865
SecondaryArea Under Plasma Concentration-time Curve From Administration to Infinity (AUC0-inf) of Ibuprofen

AUC0-inf was calculated as AUC0-t + (Ct/Kel) where Ct was the last quantifiable concentration at time t.

Time frame:
Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose
Reported as:
Mean · min*μg/mL
Area Under Plasma Concentration-time Curve From Administration to Infinity (AUC0-inf) of Ibuprofen
min*μg/mLTest (Fasted): Nurofen for ChildrenTest (Fed): Nurofen for ChildrenReference (Fasted): Algifor JuniorReference (Fed): Algifor Junior
Area Under Plasma Concentration-time Curve From Administration to Infinity (AUC0-inf) of Ibuprofen6255.821 ± 1229.64145982.084 ± 1118.93616032.841 ± 843.83795609.733 ± 862.2304
SecondaryRatio of AUC0-t/AUC0-inf (AUCR)
Time frame:
Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose
Reported as:
Mean · Ratio
Ratio of AUC0-t/AUC0-inf (AUCR)
RatioTest (Fasted): Nurofen for ChildrenTest (Fed): Nurofen for ChildrenReference (Fasted): Algifor JuniorReference (Fed): Algifor Junior
Ratio of AUC0-t/AUC0-inf (AUCR)0.987 ± 0.00660.963 ± 0.03840.988 ± 0.00520.978 ± 0.0142
SecondaryTime to Maximum Plasma Concentration (Tmax) of Ibuprofen
Time frame:
Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose
Reported as:
Mean · min
Time to Maximum Plasma Concentration (Tmax) of Ibuprofen
minTest (Fasted): Nurofen for ChildrenTest (Fed): Nurofen for ChildrenReference (Fasted): Algifor JuniorReference (Fed): Algifor Junior
Time to Maximum Plasma Concentration (Tmax) of Ibuprofen60.4 ± 43.5965.8 ± 24.7965 ± 33.8174.9 ± 42.66
SecondaryPlasma Concentration Half-life (T1/2) of Ibuprofen
Time frame:
Pre-dose (Day -1), 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480 and 720 minutes (Day 0) post-dose
Reported as:
Mean · min
Plasma Concentration Half-life (T1/2) of Ibuprofen
minTest (Fasted): Nurofen for ChildrenTest (Fed): Nurofen for ChildrenReference (Fasted): Algifor JuniorReference (Fed): Algifor Junior
Plasma Concentration Half-life (T1/2) of Ibuprofen108.854 ± 13.1303138.894 ± 41.0392104.975 ± 11.6362122.752 ± 19.338
SecondaryNumber of Subjects With Treatment Emergent Adverse Events (TEAEs)

Mild = Adverse event (AE) did not limit usual activities; subject may have experienced slight discomfort. Moderate = AE resulted in some limitation of usual activities; subject may have experienced significant discomfort. Severe = AE resulted in an inability to carry out usual activities; subject may have experienced intolerable discomfort/pain. Unassessable/Unclassified = Insufficient information to be able to make an assessment Conditional/ Unclassified = Insufficient information to make an assessment at present Unrelated = No possibility that the AE was caused by the IMP Unlikely = Slight, but remote, chance that the AE was caused by the IMP, but the balance of judgment was that it was most likely not due to the investigational medicinal product (IMP). Possible = Reasonable suspicion that the AE was caused by the IMP Probable = Most likely that the AE was caused by the IMP Certain = AE was definitely caused by the IMP

Time frame:
Up to Day 7 (follow-up)
Reported as:
Count of participants · Participants
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
ParticipantsTest (Fasted): Nurofen for ChildrenTest (Fed): Nurofen for ChildrenReference (Fasted): Algifor JuniorReference (Fed): Algifor Junior
Treatment Emergent Adverse Event (TEAE)3110
Serious TEAE0000
TEAE Leading to Withdrawal0000
TEAE by severity: Mild3110
TEAE by severity: Moderate0000
TEAE by severity: Severe0000
Relationship to IMP - Certain0000
Relationship to IMP - Probable0000
Relationship to IMP - Possible0000
Relationship to IMP - Unlikely0000
Relationship to IMP - Unrelated3110
Relationship to IMP - Conditional/Unclassified0000
Relationship to IMP - Unassessable/Unclassifiable0000

Adverse events

Collected over Up to Day 7 (Follow-up). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test (Fasted): Nurofen for Children0/24 (0%)0/24 (0%)2/24 (8.3%)
Test (Fed): Nurofen for Children0/24 (0%)0/24 (0%)1/24 (4.2%)
Reference (Fasted): Algifor Junior0/24 (0%)0/24 (0%)1/24 (4.2%)
Reference (Fed): Algifor Junior0/24 (0%)0/24 (0%)0/24 (0%)
Most frequent other events
Most frequent other events
EventTest (Fasted): Nurofen for ChildrenTest (Fed): Nurofen for ChildrenReference (Fasted): Algifor JuniorReference (Fed): Algifor Junior
HeadacheNervous system disorders1/241/241/240/24
NasopharyngitisInfections and infestations1/240/240/240/24

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Overall Study
<=18 years0
Between 18 and 65 years24
>=65 years0
Age, Continuous
Age, Continuous(years)Overall Study
Mean29.5 ± 8.21
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female13
Male11
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Study
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White22
More than one race0
Unknown or Not Reported2
Weight
Weight(kg)Overall Study
Mean68.68 ± 11.506
Height
Height(meter)Overall Study
Mean1.692 ± 0.0935
Body Mass Index
Body Mass Index(kg/m²)Overall Study
Mean23.82 ± 2.037
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in May 2016, 2 months.

Results were first posted in Jun 2019, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2018
First posted
Apr 12, 2018
StartActual
Feb 29, 2016
Primary completionActual
May 6, 2016
CompletionActual
May 6, 2016
Results first posted
Jun 5, 2019
Last update
Jun 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03496324
Responsible party
Sponsor
First posted
Apr 12, 2018
Start date
Feb 29, 2016
Primary completion
May 6, 2016
Completion
May 6, 2016
Results posted
Jun 5, 2019
Last update
Jun 5, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion